Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or After EGFR Tyrosine Kinase Receptor (TKI) Therapy.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms KOREA
- Sponsors AstraZeneca
- 04 Oct 2016 Status changed from not yet recruiting to recruiting.
- 24 May 2016 New trial record